hcg and tirzepatide FDA takes aim at "unproven" weight-loss brands HCG and Testosterone Injections at

Dietary modifications are often the most effective first-line approach

Compounded GLP-1 programs qualify for FSA and HSA coverage when they include a licensed medical evaluation, a prescription tied to a diagnosed condition, and proper documentation

In clinical trials, Zepbound Lilly's injectable tirzepatide has shown weight reduction of around 20% or more

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should avoid GLP-1 medications

Additionally, the patients in our study had no dietary restrictions in the days before the MMTT, which may influence the research outcome